

Association of genetic polymorphisms on methotrexate toxicity in patients with rheumatoid arthritis

María José Zarzuelo Romero¹, María del Mar Maldonado Montoro², Cristina Pérez Ramírez^{3*}, Noelia Márquez Pete⁴, Almudena Sánchez Martín⁴, Fernando Martínez Martínez¹, Miguel Ángel Calleja Hernández³, María Carmen Ramírez Tortosa⁵, Alberto Jiménez Morales⁴

¹Department of Pharmacy and Pharmaceutical Technology, Social and Legal Assistance Pharmacy Section, Faculty of Pharmacy, University of Granada, Granada, Spain

²Clinical Analysis Service, Hospital Campus de la Salud, Granada, Spain

³Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen Macarena, Sevilla, Spain

⁴Pharmacy Service, Pharmacogenetics Unit, University Hospital Virgen de las Nieves, UGC Provincial de Farmacia de Granada, Granada, Spain

⁵Department of Biochemistry, Faculty of Pharmacy, University of Granada, Granada, Spain

***Corresponding author:**

Cristina Pérez Ramírez PhD
University Hospital Virgen Macarena
Pharmacy Service
Dr. Fedriani 3
41009 Sevilla, Spain
Phone: +34955008000
E-mail:
cperezramirez87@gmail.com

Submitted: 16 April 2020; **Accepted:** 19 June 2020

Online publication: 17 July 2020

Arch Med Sci 2026; 22 (1): 179–187

DOI: <https://doi.org/10.5114/aoms.2020.97360>

Copyright © 2020 Termedia & Banach

Abstract

Introduction: Methotrexate (MTX) is the treatment of choice for patients with rheumatoid arthritis (RA). However, it has been found to produce toxicity in some patients. Different polymorphisms can play a part in inter-individual differences in toxicity. Our aim is therefore to determine the influence of gene polymorphisms in the MTX metabolic pathway, such as *MTHFR* (rs1801133 and rs1801131), *MTHFD1* (rs2236225), *MTR* (rs1805087), and *ABCC2* (rs4148396), on toxicity in MTX treatment among Caucasian patients diagnosed with RA.

Material and methods: Real-time polymerase chain reaction (PCR) analysis with TaqMan probes was performed on these polymorphisms in 200 patients in a retrospective study.

Results: Patients with TT genotype and C allele for *MTHFR* rs1801133 gene polymorphism presented a higher risk of anaemia ($p = 0.0304$; OR = 3.70; 95% CI: 1.10–12.34) and dizziness ($p = 0.0438$; OR = 8.15; 95% CI: 1.61–148.68). Patients with *MTHFR* rs1801131-C allele or CC genotype presented a higher risk of mucositis ($p = 0.0188$; OR = 3.02; 95% CI: 1.22–7.91), acneiform rash ($p = 0.0322$; OR = 5.74; 95% CI: 1.34–39.21), and alopecia ($p = 0.0072$; OR = 5.11; 95% CI: 1.37–17.70). Patients with *MTR* rs1805087-CC genotype presented a higher risk of anosmia ($p = 0.0038$; OR = 98.00; 95% CI: 3.16–infinite); patients with the TT genotype or T allele for *MTHFD1* rs2236225 presented a higher risk of liver failure ($p = 0.00229$; OR = 2.34; 95% CI: 1.14–4.96) and alopecia ($p = 0.0248$; OR = 3.83; 95% CI: 1.10–13.30), and patients with the TT genotype for *ABCC2* rs4148396 polymorphism ($p = 0.0466$; OR = 2.67; 95% CI: 0.98–6.94) presented a higher risk of headaches.

Conclusions: Pharmacogenomic analysis of these polymorphisms may facilitate decision-making in relation to MTX treatment toxicity among RA patients.

Key words: rheumatoid arthritis, methotrexate, toxicity, polymorphisms.

Introduction

Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease characterised by inflammation of the synovial membrane in joints, causing joint destruction and consequently pain and functional disability, diminishing quality of life among patients [1–5]. RA affects approximately 0.5% of the adult population globally [6, 7]. The disease is predominantly treated using disease-modifying anti-rheumatic drugs (DMARDs) and nonsteroidal anti-inflammatory drugs (NSAIDs) [8, 9]. These drugs act by reducing inflammation and delaying bone erosion, and, therefore, they slow down the progression of the disease [10]. Methotrexate (MTX) is the first-line treatment for this disease both as monotherapy and as an adjuvant to biological therapies, due to its high efficacy and rapid action [11, 12]. However, there is considerable interindividual variability in MTX toxicity [13]. Previous studies have found that one-third of patients on MTX treatment do not reach the therapeutic goal due to lack of response to the drug, development of toxicity or loss of efficacy over time [14–17]. Among the most frequent adverse effects are gastrointestinal disorders, liver toxicity, skin reactions, and bone marrow disorders [18, 19]. The factors responsible for this variable toxicity in MTX treatment are not yet fully understood, but recently the genetic polymorphisms linked to the MTX metabolic pathway have become the targets of study for understanding MTX toxicity [20–24].

MTX is a folic acid analogue with anti-inflammatory and anti-proliferative properties [25, 26]. It acts by inhibiting various enzymes in the synthesis pathway of folate, methionine, adenosine, and nucleotides [25], significant among which is methylenetetrahydrofolate reductase (MTHFR). The protein encoded by this gene catalyses the conversion of 5,10-methylenetetrahydrofolate to 5-methyltetrahydrofolate, a co-substrate for homocysteine remethylation to methionine [27]. Two polymorphisms in this enzyme play a part in metabolising MTX. SNP (Single Nucleotide Polymorphism) *MTHFR* 677C>T (rs1801133) leads to the substitution of alanine for valine at position 233 (Ala233Val) of the protein, reducing the activity of the enzyme. Previous studies have found a link between TT+CT genotypes and MTX liver toxicity, due to increased serum levels of liver enzymes and homocysteine [28, 29]. Another of the polymorphisms studied is *MTHFR* 1298A>C (rs1801131), which leads to the substitution of glutamine for alanine at codon 429 (Glu429Ala). The G allele has previously been linked to increased risk of adverse effects such as neurotoxicity and liver toxicity [30, 31]. The methylenetetrahydrofolate dehydrogenase 1 (*MTHFD1*) encodes a protein that possesses three distinct

enzymatic activities: 5,10-methylenetetrahydrofolate dehydrogenase, 5,10-methenyltetrahydrofolate cyclohydrolase, and 10-formyltetrahydrofolate synthetase. Each of these activities catalyses one of three sequential reactions in the interconversion of 1-carbon derivatives of tetrahydrofolate, which are substrates for methionine, thymidylate, and de novo purine syntheses. The polymorphism 1958G>A (rs2236225) leads to the substitution of arginine for glycine at gene position 653 (Arg653Gln), reducing the enzymatic activity of the complex [32]. Another enzyme found on the folic acid metabolic pathway is 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR), also known as cobalamin-dependent methionine synthase, which catalyses the final step in methionine biosynthesis [28]. An SNP in *MTR* gene (2756A>G rs1805087) has been found to reduce enzyme activity [33, 34].

MTX is transported across the cell membrane by a series of transporter proteins, significant amongst which are ABCB1 (P-glycoprotein) and multidrug resistance-associated protein 2 (ABCC2). The membrane-associated proteins encoded by these genes are members of the superfamily of ATP-binding cassette (ABC) transporters. ABC proteins transport various molecules across extra- and intra-cellular membranes [35]. The *ABCB1* 3435C>T (rs1045642) gene polymorphism has been found to affect response to the drug; specifically, genotype CC could play a part in reducing response to therapy [36]. Similarly, the CT genotype has been linked to increased risk of gastrointestinal toxicity in 336 RA patients of Indian origin [37]. Another of the polymorphisms involved is (rs4148396) in the *ABCC2* gene, a transporter protein involved in eliminating metabolites and located on the surface of hepatocytes, the intestine, and the proximal tubules [38]. In a study on 309 Caucasian RA patients on MTX treatment, the CC genotype was found to be associated with increased risk of alopecia [39]. Finally, an SNP in *TLR4* (Toll-4 receptor) (896A>G; rs4986790) gene, which codified a protein member of the Toll-like receptor (TLR) family and plays a fundamental role in pathogen recognition and activation of innate immunity, has been linked to the development of mucositis in patients being treated with folic acid and MTX [40].

This was the conceptual framework for our study evaluating the influence of polymorphisms in the genes along the MTX metabolic pathway, including *MTHFR* 677C>T (rs1801133), 1298A>C (rs1801131), *MTHFD1* 1958G>A (rs2236225), *MTR* 2756A>G (rs1805087), *ABCB1* 3435C>T (rs1045642), *ABCC2* C>T (rs4148396), and *TLR4* 896A>G (rs4986790), on specific types of toxicity of MTX treatment that have not been previously described among Caucasian RA patients.

Material and methods

Study design

An observational, retrospective cohort study conducted in the Virgen de las Nieves University Hospital in Granada (HUVN) with the approval of the reference Ethics Committee in compliance with the Helsinki Declaration. Informed consent was obtained from all patients prior to their inclusion in the study, and their data were treated confidentially.

Target population

The study recruited 200 Caucasian patients, aged over 18 years, and diagnosed with RA as per American College of Rheumatology (ACR) criteria, who were on, or had been on, MTX treatment for at least 1 month. The initial dose was 15 mg/week orally, with escalation from 5 mg/month to 25–30 mg/week or to the maximum tolerable dose. In the case of an insufficient response it was changed to subcutaneous administration [41, 42].

Study location and timeframe

Patients diagnosed with RA and on MTX treatment between February 1990 and June 2018, in HUVN Rheumatology and Pharmacy Departments.

Sociodemographic and clinical variables

The data collected were: sex, age when diagnosed with RA, duration of MTX treatment, smoking status, baseline rheumatoid factor (RF) value, baseline DAS28 [43] value, and adverse reactions relating to blood disorders (anaemia, neutropenia, macrocytosis, and thrombocytopenia), smelling (anosmia), digestive system (diarrhoea, nausea and vomiting, mucositis), liver failure, nervous system (dizziness and headaches), psychiatric disorders (anxiety), reproductive system (metrorrhagia), respiratory disorders (pulmonary fibrosis), and skin and subcutaneous tissue disorders (alopecia and acneiform rash).

EULAR response was according to the guidelines given by the European League Against Rheumatism, and was classified as satisfactory (presenting DAS28 < 3.2 and DAS28 improvement > 1.2) or unsatisfactory (presenting DAS28 ≥ 3.2 and DAS28 improvement ≥ 1.2).

Remission and low disease activity were considered when patients achieved DAS28 < 2.4 and DAS28 < 3.6, respectively.

Genetic variables

DNA isolation

Saliva samples were collected in 50 ml BD Falcon™ conical tubes (BD, Plymouth, UK). DNA isolation

was performed using the QIAamp DNA Mini Kit (Qiagen GmbH, Hilden, Germany) according to the manufacturer's instructions for DNA purification from blood or saliva and stored at –40°C.

Detection of genetic polymorphisms

The genetic polymorphisms identified as being involved in MTX toxicity—*ABCB1* 3435C>T (rs1045642), *ABCC2* C>T (rs4148396), *MTHFR* 677C>T (rs1801133), *MTHFR* 1298A>C (rs1801131), *MTR* 2756A>G (rs1805087), *MTHFD1* 1958G>A (rs2236225) and *TLR4* 896A>G (rs4986790) – were analysed using real-time PCR with TaqMan® probes. The assay ID used for gen *ABCB1* (rs1045642) is C_7586657_20, for *ABCC2* (rs4148396) is C_11305432_10, for *MTHFR* (rs1801133) is C_1202883_20, for *MTHFR* (rs1801131) is C_850486_20, for *MTR* (rs1805087) is C_12005959_10, for *MTHFD1* (rs2236225) is C_1376137_10, and for *TLR4* (rs4986790) is C_11722238_20.

Toxicity variables

Toxicity was evaluated using version 4.0 of Common Terminology Criteria for Adverse Events (CTCAE). According to the severity of the adverse reaction, it was graded 0–2 and 3–4. This study considered adverse events of grade 3–4, dichotomised into the presence or absence of type of adverse reaction.

Statistical analysis

Quantitative data were expressed as mean (± standard deviation) for normal-distribution variables or medians and percentiles (25 and 75) for non-normal-distribution variables.

Bivariate analysis was used to evaluate the link between toxicity and polymorphisms using Fisher's exact test and odds ratio (OR) with the appropriate 95% confidence interval (CI).

Differences in distribution of genotypes for toxicity were analysed using 3 × 2 tables for each genotype. Values of $p < 0.05$ were considered statistically significant. Strength of association between RA patients and genotypes was estimated using relative risk (RR) with 95% CI.

Descriptive analysis was performed using R 3.0.1 [44].

The Hardy-Weinberg equilibrium and pairwise haplotype frequencies were estimated using the free, open-source whole genome association analysis toolset PLINK [45].

Results

Patient characteristics

The baseline characteristics of the 200 RA patients are shown in Table I. Median age was

Table I. Clinical-pathological characteristics of the 200 RA patients treated with methotrexate

Parameter	N	%	Parameter	N	%
Gender:			Nausea and vomiting:		
Female	161	80.5	Yes	46	23.0
Male	39	19.5	No	154	77.0
Age at AR diagnosis [years]:	45 (35–53)		Mucositis:		
≤ 45	102	51.0	Yes	22	11.0
> 45	98	49.0	No	178	89.0
Duration of methotrexate treatment [months]:	46 (17–88)		Hepatobiliary disorders:		
≤ 46	102	51.0	Liver failure:		
> 46	98	49.0	Yes	90	46.4
Smoking status:			No	104	53.6
Current-smokers	45	22.5	Nervous system disorders:		
Former-smokers	12	6.0	Dizziness:		
Non-smokers	143	71.5	Yes	18	9.0
Baseline FR status:			No	182	91.0
Negative	63	31.7	Headache:		
Positive	136	68.3	Yes	20	10
Baseline DAS28 status	5.42 ± 1.15		No	180	90
≤ 5.42	98	49.3	Psychiatric disorders:		
> 5.42	101	50.7	Anxiety:		
Blood system disorders:			Yes	1	0.5
Anaemia:			No	199	99.5
Yes	12	6.0	Reproductive system and breast disorders:		
No	188	94.0	Metrorrhagia		
Neutropaenia:			Yes	3	1.5
Yes	15	7.5	No	197	98.5
No	185	92.5	Respiratory, thoracic and mediastinal disorders:		
Macrocytosis:			Pulmonary fibrosis		
Yes	5	2.5	Yes	7	3.5
No	195	97.5	No	193	96.5
Thrombocytopaenia:			Skin and subcutaneous tissue disorders:		
Yes	3	1.5	Alopecia:		
No	197	98.5	Yes	25	12.5
Smell disorders:			No	175	87.5
Anosmia:			Rash acneiform:		
Yes	2	1	Yes	9	4.5
No	198	99	No	191	95.5
Gastrointestinal disorders:					
Diarrhoea:					
Yes	32	16.0			
No	168	84.0			

Qualitative variables: number (percentage). Quantitative variables: Normal distribution: mean ± standard deviation. Non-normal distribution: P_{50} [P_{25} P_{75}].

45 years (35, 53), 161 were female (161/200; 80.5%), and 143 were non-smokers (143/200; 71.5%). The median of the duration on MTX treatment was 46 months (17, 88). As regards the baseline RF value, it was positive for 68.3% (63/199) of patients, and for RA activity analysed by DAS28 value the mean obtained was 5.42 ±1.15. The grade 3–4 toxicity profile value was: 6.0% (12/200) anaemia, 7.5% (15/200) neutropaenia, 2.5% (5/200) macrocytosis, 1.5% (3/200) thrombocytopenia, 1% (2/200) anosmia, 16.0% (32/200) diarrhoea, 23.0% (46/200) nausea and vomiting, 11.0% (22/200) mucositis, 46.4% (90/200) liver failure, 9.0% (18/194) dizziness, 10.0% (20/200) headache, 0.5% (1/200) anxiety, 1.5% (3/200) metrorrhagia, 3.5% (7/200) pulmonary fibrosis, 12.5% (25/200) alopecia, and 4.5% (9/200) acneiform rash (Table I).

Influence of clinical-pathological characteristics on toxicity

Nausea and vomiting showed a statistically significant association with treatment duration ($p = 0.0423$; OR = 2.13; 95% CI: 1.03–4.54) (Supplementary Table SI). No association was observed between the other toxicities and patient clinical-pathological characteristics (Supplementary Tables SII–SXVI).

Genotyping distribution

The distribution of all the polymorphisms studied match what is expected as per the Hardy-Weinberg equilibrium model (Supplementary Table SXVII). The linkage disequilibrium D' and r^2 values are shown in Supplementary Table SXVIII.

Influence of polymorphisms on toxicity

Haematological toxicity

Bivariate analysis showed that patients with CC genotype for *ABCC2* rs4148396 polymorphism were at greater risk of developing macrocytosis ($p = 0.0022$) (Supplementary Table SXIX). The multivariate logistic regression model revealed the influence of this polymorphism on macrocytosis (Table II). In the bivariate analysis, *MTHFR* rs1801133 was associated with anaemia. In particular, patients with the TT genotype were at greater risk of anaemia ($p = 0.0328$; OR = 3.70; 95% CI: 1.3–12.09) (Supplementary Table SXX). This association was also clear in the multivariate logistic regression analysis (Table II). Other haematological toxicities (neutropaenia and thrombocytopenia) showed no significant association with the polymorphisms analysed (Supplementary Tables SXXI, SXXII).

Nervous system toxicity

Bivariate analysis showed that the *MTHFR* rs1801133 and *ABCC2* rs4148396 gene polymorphisms were associated with a higher risk of dizziness and headaches, respectively. Specifically, patients with *MTHFR* rs1801133-T allele were at greater risk of experiencing dizziness ($p = 0.0355$; OR = 8.15; 95% CI: 1.06–62.75) (Supplementary Table SXXIII). Similarly, patients with *ABCC2* rs4148396-TT genotype were at greater risk of experiencing headaches ($p = 0.0496$; OR = 2.67; 95%CI: 0.01–7.01) (Supplementary Table SXXIV). Multivariate logistic regression analysis was conducted to evaluate the impact of these polymorphisms on nervous system toxicity, and both were found to be statistically significant (Table II).

Other toxicity subtypes

Bivariate analysis showed that patients with *MTHFR* rs1801131-C allele were at greater risk of developing mucositis and acneiform rash ($p = 0.02765$; OR = 3.02; 95% CI: 1.20–7.57 and $p = 0.0307$; OR = 5.74; 95% CI: 1.16–28.27, respectively) (Supplementary Tables SXXV, SXXVI). The multivariate logistic regression model showed that *MTHFR* rs1801131 was the only independent factor associated with developing mucositis and

Table II. The influence of gene polymorphisms on toxicity

Parameter	OR (95% CI)	P-value
Anaemia:		
MTHFR rs1801133-TT	3.70 (1.10–12.43)	0.0304
Anosmia:		
MTR rs1805087-CC	98.00 (3.16–Inf)	0.0038
Alopecia:		
MTHFD1 rs2236225-T	4.47 (1.41–20.24)	0.0229
MTHFR rs1801131-CC	6.20 (1.84– 20.53)	0.0025
Mucositis:		
MTHFR rs1801131-C	3.02 (1.22–7.91)	0.0188
Liver failure:		
MTHFD1 rs2236225-TT	2.34 (1.14–4.96)	0.0229
Dizziness:		
MTHFR rs1801133-C	8.15 (1.61–148.68)	0.0438
Headache:		
ABCC2 rs4148396-TT	2.67 (0.98–6.94)	0.0466
Rash acneiform:		
MTHFR rs1801131-C	5.74 (1.34–39.21)	0.0322

Inf – Infinite.

acneiform rash (Table II). In the bivariate analysis, patients with *MTR* rs1805087-CC genotype were at greater risk of developing anosmia ($p = 0.0298$; RR = 98.00; 95% CI: 4.41–2180.05) (Supplementary Table SXXVII), which was confirmed in the multivariate analysis (Table II). In the bivariate analysis, patients with *MTHFD1* rs2236225-T allele and *MTHFR* rs1801131-CC genotype were at greater risk of developing alopecia ($p = 0.0248$; OR = 3.83; 95% CI: 1.10–13.30 and $p = 0.0072$; OR = 5.11; 95% CI: 1.37–17.70, respectively) (Supplementary Table SXXVIII), which was statistically significant in the multivariate analysis (Table II). Liver failure was associated with *MTHFD1* rs2236225 gene polymorphism. Patients with *MTHFD1* rs2236225-TT genotype showed higher toxicity due to liver failure ($p = 0.0332$; OR = 2.34; 95% CI: 1.12–4.86) (Supplementary Table SXXIX). The multivariate logistic regression analysis showed that the *MTHFD1* rs2236225 gene polymorphism was the only independent factor associated with liver failure (Table II).

For the remaining polymorphisms, no significant associations were found between the genotype and appearance of toxicity (Supplementary Tables SXXX–SXXXIV).

Discussion

Over 2 million patients experience adverse reactions to medication annually, with around 197,000 deaths as a result [46]. In the case of RA, MTX is the first-line treatment, but 30% of RA patients on MTX therapy cease treatment due to side effects such as liver failure or gastrointestinal disorders. Furthermore, there is considerable variability between patients as regards developing toxicity, which limits treatment [47–50]. Among the causes leading to this variability are polymorphisms in the genes in the MTX metabolic pathway [51–59].

This study included 200 RA patients in a single institution, who had been on MTX treatment for at least one month, with a view to investigating the influence of polymorphisms in *ABCB1*, *ABCC2*, *MTHFR*, *MTR*, *MTHFD1*, and *TLR4* genes on the risk of developing drug-related toxicity. Among these patients, *MTHFR* rs1801133-C allele and TT genotype, *MTHFR* rs1801131-C allele and CC genotype, *MTR* rs1805087-CC genotype, *MTHFD1* rs2236225-TT genotype and T allele, and *ABCC2* rs4148396-TT genotype are all predictors of at least one grade 3–4 adverse reaction developing (Table II).

The influence of polymorphisms in *MTHFR* (rs1801131 and rs1801133) on MTX toxicity has been extensively researched [31, 60, 61]. In our study, the polymorphism rs1801133 has been associated with the development of anaemia

in patients with the TT genotype ($p = 0.0304$; OR = 3.70; 95% CI: 1.10–12.43) and of experiencing dizziness in patients with the C allele ($p = 0.0438$; OR = 8.15; 95% CI: 1.61–148.68). No previous studies have assessed the effect of this polymorphism on both toxicity subtypes in RA patients on MTX therapy. In line with our findings, a previous study in India on 236 RA patients treated with MTX found a link between the T allele for *MTHFR* rs1801133 and the development of general toxicity (RR = 2.01; 95% CI: 1.09–3.70), primarily with increased levels of liver enzymes (RR = 2.38; 95% CI: 1.06–5.34) [28]. Similarly, a study on Caucasian patients with osteosarcoma (63 patients) and acute lymphoblastic leukaemia (52 patients) on MTX therapy showed a link between the T allele and liver toxicity ($p = 0.04$; OR = 1.8; 95% CI: 1.0–3.2) [61]. In relation to *MTHFR* rs1801131, our study revealed a significant link between the C allele and the risk of developing acneiform rash ($p = 0.0322$; OR = 5.74; 95% CI: 1.34–39.21) and mucositis ($p = 0.0188$; OR = 3.02; 95% CI: 1.22–7.91). Patients carrying the CC genotype also showed greater risk of developing alopecia ($p = 0.0072$; OR = 5.11; 95% CI: 1.37–17.70). The link between this polymorphism and the development of dermatological toxicity has not been previously studied. However, in line with our findings, a study on 1004 Asian patients with lung cancer receiving platinum-based chemotherapy found a link between patients with the CT genotype and the development of gastrointestinal toxicity ($p = 0.004$, OR = 0.40; 95% CI: 0.22–0.75) [20].

In relation to *MTHFD1* rs2236225 gene polymorphism, we found an association between the *MTHFD1* rs2236225-T allele and the risk of alopecia ($p = 0.0248$; OR = 3.83; 95% CI: 1.10–13.30) as well as between the *MTHFD1* rs2236225-TT genotype and risk of liver failure ($p = 0.0229$; OR = 2.34; 95% CI: 1.14–4.96). Liver failure is the most frequently occurring adverse reaction and therefore the one that causes the most concern for MTX treatment, and alopecia is another frequent side effect, but there are no previous studies that assess the effect of *MTHFD1* rs2236225 polymorphism on liver toxicity or alopecia in RA patients. However, its effect in 41 patient from Slovenia with pleural mesothelioma has been assessed regarding response to pemetrexed treatment, which was found to be lower in patients with the T allele ($p = 0.0005$; OR = 0.12; 95% CI: 0.03–0.54) [62].

As regards *ABCC2* rs4148396 polymorphism, our study showed a link between the TT genotype and greater risk of experiencing headaches ($p = 0.0466$; OR = 2.67; 95% CI: 0.98–6.94). The effect of this polymorphism on central nervous system toxicity has not been studied previously in RA patients, although its association with toxicity has

been evaluated in a study on 154 Caucasian patients with colorectal cancer receiving chemotherapy (5-fluorouracil/leucovorin/oxaliplatin), which revealed a correlation between the T allele of *ABCC2* rs4148396 and neurotoxicity ($p = 0.0048$; OR = 4.69; 95% CI: 1.60–13.74) [63].

Another of the MTX metabolic pathway polymorphisms analysed is *MTR* rs1805087. We found a link between the CC genotype of this polymorphism and anosmia ($p = 0.0038$; OR = 98.00; 95% CI: 3.16–infinite); however, the sample size was only 2 patients. There are no previous studies that evaluate the role of this polymorphism in developing anosmia, but its role as a biomarker for gastrointestinal disorders and liver toxicity has been evaluated in 405 European patients, and although no significant differences were found in this respect, they were found in the time taken for disease to become inactive ($p = 0.042$; OR = 1.64; 95% CI: 1.02–2.63) [64].

Lastly, other polymorphisms analysed for which we found no significant differences are *ABCB1* rs1045642 and *TLR4* rs4986790. In line with our findings, various studies have assessed the role of the *ABCB1* rs1045642 polymorphism in patients receiving platinum-based chemotherapy. A study on 120 Caucasian patients with colorectal cancer on oxaliplatin therapy evaluated the effect of *ABCB1* rs1045642 gene polymorphism on neurotoxicity, finding no significant differences ($p = 0.951$; OR = 0.97; 95% CI: 0.39–2.41) [65]. Another study on 141 patients with non-small-cell lung cancer receiving carboplatin/cisplatin treatment studied the effect of this polymorphism on different toxicity sub-types (asthenia, gastrointestinal toxicity, liver toxicity, infection, nephrotoxicity, and neurotoxicity) and found no significant association [66]. For *TLR4* rs4986790 gene polymorphism, a study on 1481 RA patients found no significant association between this polymorphism and toxicity relating to cardiovascular risk, which is in line with our findings [67].

The patients included in our study were recruited from the same hospital, which ensures sample homogeneity as regards treatment and period of administration, and toxicity data. Its main limitation relates to sample size, due to the small number of patients showing a link between some of the polymorphisms described and toxicity.

This notwithstanding, and given that there are currently no tests available for predicting MTX toxicity, it may be concluded that pharmacogenetic studies of the polymorphisms involved in MTX metabolic pathways may be clinically useful for rheumatologists as an aid for making decisions regarding therapy, such as dose adjustment or concomitant administration of folic or folinic acid, or an alternative treatment. In this way, therapeutic algorithms for RA that may integrate clinical,

genetic, and other biomarker data are critically important to individualise and optimise therapy with antirheumatic agents. In this regard, the next crucial step is the clinical verification of these promising biomarkers using studies that assess multiple SNPs, longer-term follow-up, and larger sample sizes. Therefore, further research is needed to clarify the true role of these polymorphisms in the toxicity to MTX therapy in AR patients.

Moreover, along with the growing pharmacogenetic knowledge in rheumatology, there is increasing difficulty to explain to physicians the use, advantages, and disadvantages of pharmacogenetics and how to interpret and apply genetic test result to guide drug therapy decisions. Thus, effective health education for physicians is required for a successful choice and/or adjustment of antirheumatic agents and for an understandable information towards the patients.

In conclusion, these results suggest that RA patients treated with MTX, who have *MTHFR* rs1801133-TT genotype, are at higher risk of developing anaemia. Patients with *MTHFR* rs1801133-C allele are at greater risk of experiencing dizziness, and patients with *MTHFR* rs1801131-C allele or CC genotype are at greater risk of developing mucositis, acneiform rash, and alopecia. Our results also revealed that patients with *MTHFD1* rs2236225-T allele or TT genotype are at greater risk of liver failure and alopecia. Similarly, the TT genotype of *ABCC2* rs4148396 gene polymorphism conferred higher risk of suffering headaches in our patients.

Acknowledgments

María del Mar Maldonado Montoro and Cristina Pérez Ramírez contributed equally to the work. Ángel Calleja Hernández, María Carmen Ramírez Tortosa and Alberto Jiménez Morales also contributed equally to the work.

Funding

No external funding.

Conflict of interest

The authors declare no conflict of interest.

References

- McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. *N Engl J Med* 2011; 365: 2205-19.
- Malinowski D, Paradowska-Gorycka A, Safranow K, Pawlik A. Interleukin-21 gene polymorphism rs2221903 is associated with disease activity in patients with rheumatoid arthritis. *Arch Med Sci* 2017; 13: 1142-7.
- Baczyk G, Kozłowska K. The role of demographic and clinical variables in assessing the quality of life of outpatients with rheumatoid arthritis. *Arch Med Sci* 2018; 14: 1070-9.

4. Balbaloglu O, Ozcan SS. Is pentraxin 3 level an effective biomarker in disease activity in patients with rheumatoid arthritis? *Arch Med Sci* 2020; 16: 81-6.
5. Dervisevic A, Resic H, Sokolovic S, et al. Leptin is associated with disease activity but not with anthropometric indices in rheumatoid arthritis patients. *Arch Med Sci* 2018; 14: 1080-6.
6. Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. *Lancet* 2017; 389: 2338-48.
7. Batko B, Stajszczyk M, Swierkot J, et al. Prevalence and clinical characteristics of rheumatoid arthritis in Poland: a nationwide study. *Arch Med Sci* 2019; 15: 134-40.
8. Tlustochowicz M, Sliwczynski AM, Brzozowska M, Teter Z, Marczak M. Sequentiality of treatment in the rheumatoid arthritis drug programme in the years 2009-2014. *Arch Med Sci* 2018; 14: 569-71.
9. Ma K, Li L, Liu C, Zhou L, Zhou X. Efficacy and safety of various anti-rheumatic treatments for patients with rheumatoid arthritis: a network meta-analysis. *Arch Med Sci* 2019; 15: 33-54.
10. Owen S, Lunt M, Bowes J, et al. MTHFR gene polymorphisms and outcome of methotrexate treatment in patients with rheumatoid arthritis: analysis of key polymorphisms and meta-analysis of C677T and A1298C polymorphisms. *Pharmacogenomics J* 2013; 13: 137.
11. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. *Arthritis Rheum* 1990; 33: 1449-61.
12. Kremer JM. Toward a better understanding of methotrexate. *Arthritis Rheum* 2004; 50: 1370-82.
13. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses. *Rheumatology* 2002; 41: 1367-74.
14. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis* 2009; 68: 1100-4.
15. Tian H, Cronstein BN. Understanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritis. *Bull NYU Hosp Jt Dis* 2007; 65: 168-73.
16. Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review. *Eur J Med Chem* 2018; 158: 502-16.
17. Labadie JG, Hashim R, Raheel S, Awad L, Jain M. A 2018 approach to combating methotrexate toxicity folic acid and beyond. *Bull Hosp Jt Dis* 2018; 76: 151-5.
18. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study. *Arthritis Rheum* 1994; 37: 1492-8.
19. Walker AM, Funch D, Dreyer NA, et al. Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. *Arthritis Rheum* 1993; 36: 329-35.
20. Li X, Shao M, Wang S, et al. Heterozygote advantage of methylenetetrahydrofolate reductase polymorphisms on clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with platinum-based chemotherapy. *Tumour Biol* 2014; 35: 11159-70.
21. Shao W, Yuan Y, Li Y. Association between MTHFR C677T polymorphism and methotrexate treatment outcome in rheumatoid arthritis patients: a systematic review and meta-analysis. *Genetic Testing Mol Biomarkers* 2017; 21: 275-85.
22. Lee Y, Bae SC, Song G. Association of the ABCB1 C3435T polymorphism with responsiveness to and toxicity of DMARDs in rheumatoid arthritis. *Zeitschrift fur Rheumatologie* 2016; 75: 707-15.
23. Bae SC, Lee YH. TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis. *Zeitschrift fur Rheumatologie* 2018; 77: 824-32.
24. Bohanec Grabar P, Logar D, Lestan B, Dolzan V. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. *Eur J Clin Pharmacol* 2008; 64: 1057-68.
25. Inoue K, Yuasa H. Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy. *Drug Metabol Pharmacokinet* 2014; 29: 12-9.
26. Dogru A, Naziroglu M, Cig B. Modulator role of infliximab and methotrexate through the transient receptor potential melastatin 2 (TRPM2) channel in neutrophils of patients with rheumatoid arthritis: a pilot study. *Arch Med Sci* 2019; 15: 1415-24.
27. Brinker RR, Ranganathan P. Methotrexate pharmacogenetics in rheumatoid arthritis. *Clin Exp Rheumatol* 2010; 28 (5 Suppl 61): S33-9.
28. Chaabane S, Messedi M, Akrouf R, et al. Association of hyperhomocysteinemia with genetic variants in key enzymes of homocysteine metabolism and methotrexate toxicity in rheumatoid arthritis patients. *Inflammation Res* 2018; 67: 703-10.
29. van Ede AE, Laan RF, Blom HJ, et al. The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients. *Arthritis Rheum* 2001; 44: 2525-30.
30. Dervieux T, Wessels JA, van der Straaten T, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. *Pharmacogenet Genom* 2009; 19: 935-44.
31. Mena JP, Salazar-Paramo M, Gonzalez-Lopez L, et al. Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases. *Pharmacogenomics J* 2011; 11: 287-91.
32. Krajcinovic M. MTHFD1 gene: role in disease susceptibility and pharmacogenetics. *Pharmacogenomics* 2008; 9: 829-32.
33. Leclerc D, Campeau E, Goyette P, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/cobalamin disorders. *Human Mol Genet* 1996; 5: 1867-74.
34. Zara-Lopes T, Galbiatti-Dias ALS, Castanhole-Nunes MMU, et al. Polymorphisms in MTHFR, MTR, RFC1 and C5S genes involved in folate metabolism and thyroid cancer: a case-control study. *Arch Med Sci* 2019; 15: 522-30.
35. Pawlik A, Wrzesniewska J, Fiedorowicz-Fabrycy I, Gawronska-Szklarz B. The MDR1 3435 polymorphism in patients with rheumatoid arthritis. *Int J Clin Pharmacol Ther* 2004; 42: 496-503.
36. Chen Y, Zou K, Sun J, Yang Y, Liu G. Are gene polymorphisms related to treatment outcomes of methotrexate in patients with rheumatoid arthritis? A systematic review and meta-analysis. *Pharmacogenomics* 2017; 18: 175-95.
37. Muralidharan N, Antony PT, Jain VK, Mariaselvam CM, Negi VS. Multidrug resistance 1 (MDR1) 3435C> T gene polymorphism influences the clinical phenotype and methotrexate-induced adverse events in South Indian

- Tamil rheumatoid arthritis. *Eur J Clinl Pharmacol* 2015; 71: 959-65.
38. Rau T, Erney B, Göres R, Eschenhagen T, Beck J, Langer T. High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. *Clin Pharmacol Ther* 2006; 80: 468-76.
 39. Ranganathan P, Culverhouse R, Marsh S, et al. Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. *J Rheumatol* 2008; 35: 572-9.
 40. Kooloos WM, Wessels JA, van der Straaten T, Allaart CF, Huizinga TW, Guchelaar HJ. Functional polymorphisms and methotrexate treatment outcome in recent-onset rheumatoid arthritis. *Pharmacogenomics* 2010; 11: 163-75.
 41. Walker UA, Jaeger VK, Chatzidionysiou K, et al. Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. *Rheumatology* 2016; 55: 230-6.
 42. Smolen JS, Landewe R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. *Ann Rheum Dis* 2017; 76: 960-77.
 43. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995; 38: 44-8.
 44. Jana M, Pahan K. IL-12 p40 homodimer, but not IL-12 p70, induces the expression of IL-16 in microglia and macrophages. *Mol Immunol* 2009; 46: 773-83.
 45. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. *Am J Human Genet* 2007; 81: 559-75.
 46. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. *JAMA* 1998; 279: 1200-5.
 47. Kerstens PJ, Boerbooms AM, Jeurissen ME, Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases. *J Rheumatol* 1992; 19: 867-71.
 48. McKendry RJ, Dale P. Adverse effects of low dose methotrexate therapy in rheumatoid arthritis. *J Rheumatol* 1993; 20: 1850-6.
 49. Lucas CJ, Dimmitt SB, Martin JH. Optimising low-dose methotrexate for rheumatoid arthritis – a review. *Br J Clin Pharmacol* 2019; 85: 2228-34.
 50. Friedman B, Cronstein B. Methotrexate mechanism in treatment of rheumatoid arthritis. *Joint Bone Spine* 2019; 86: 301-7.
 51. Aggarwal P, Naik S, Mishra KP, Aggarwal A, Misra R. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. *Indian J Med Res* 2006; 124: 521-6.
 52. Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. *Ann Rheum Dis* 1999; 58: 79-84.
 53. Kim SK, Jun JB, El-Sohemy A, Bae SC. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. *J Rheumatol* 2006; 33: 1266-74.
 54. Kumagai K, Hiyama K, Oyama T, Maeda H, Kohno N. Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis. *Int J Mol Med* 2003; 11: 593-600.
 55. Kurzawski M, Pawlik A, Safranow K, Herczynska M, Drozdziak M. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. *Pharmacogenomics* 2007; 8: 1551-9.
 56. Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. *Pharmacogenet Genomics* 2007; 17: 383-90.
 57. Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. *Pharmacogenetics* 2002; 12: 183-90.
 58. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. *Arthritis Rheum* 2006; 54: 1087-95.
 59. Berkun Y, Levartovsky D, Rubinow A, et al. Methotrexate related adverse effects in patients with rheumatoid arthritis are associated with the A1298C polymorphism of the MTHFR gene. *Ann Rheum Dis* 2004; 63: 1227-31.
 60. Dervieux T, Wessels JA, van der Straaten T, et al. Gene-gene interactions in folate and adenosine biosynthesis pathways affect methotrexate efficacy and tolerability in rheumatoid arthritis. *Pharmacogenet Genomics* 2009; 19: 935-44.
 61. Hagleitner MM, Coenen MJ, Aplenc R, et al. The role of the MTHFR 677C>T polymorphism in methotrexate-induced liver toxicity: a meta-analysis in patients with cancer. *Pharmacogenomics J* 2014; 14: 115-9.
 62. Goricar K, Kovac V, Dolzan V. Polymorphisms in folate pathway and pemetrexed treatment outcome in patients with malignant pleural mesothelioma. *Radiol Oncol* 2014; 48: 163-72.
 63. Cecchin E, D'Andrea M, Lonardi S, et al. A prospective validation pharmacogenomic study in the adjuvant setting of colorectal cancer patients treated with the 5-fluorouracil/leucovorin/oxaliplatin (FOLFOX4) regimen. *Pharmacogenomics J* 2013; 13: 403-9.
 64. Zajc Avramovic M, Dolzan V, Toplak N, Accetto M, Lusa L, Avcin T. Relationship between polymorphisms in methotrexate pathway genes and outcome of methotrexate treatment in a cohort of 119 patients with juvenile idiopathic arthritis. *J Rheumatol* 2017; 44: 1216-23.
 65. Nichetti F, Falvella FS, Miceli R, et al. Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients? *Pharmacogenomics J* 2019; 19: 465-72.
 66. Perez-Ramirez C, Canadas-Garre M, Alnatsa A, et al. Pharmacogenetics of platinum-based chemotherapy: impact of DNA repair and folate metabolism gene polymorphisms on prognosis of non-small cell lung cancer patients. *Pharmacogenomics J* 2019; 19: 164-77.
 67. Garcia-Bermudez M, Lopez-Mejias R, Gonzalez-Juanatey C, et al. Lack of association between TLR4 rs4986790 polymorphism and risk of cardiovascular disease in patients with rheumatoid arthritis. *DNA Cell Biol* 2012; 31: 1214-20.